ALK and non-small cell lung carcinoma: More specifically, oncogenic drivers such as activating mutations of the epidermal growth factor receptor (EGFR), as well as rearrangements of the anaplastic lymphoma kinase (ALK) or ROS proto-oncogene 1 (ROS1) are crucial targets for biological therapies in selected subgroups of NSCLC patients [1].